J. W. Coons Advisors LLC Has $3.22 Million Stake in Stryker Corporation $SYK

J. W. Coons Advisors LLC grew its position in shares of Stryker Corporation (NYSE:SYK) by 145.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,128 shares of the medical technology company’s stock after buying an additional 4,810 shares during the quarter. J. W. Coons Advisors LLC’s holdings in Stryker were worth $3,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Stryker during the 2nd quarter valued at about $26,000. Sachetta LLC lifted its holdings in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Ridgewood Investments LLC lifted its holdings in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares during the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Stryker during the 1st quarter valued at about $37,000. Finally, Solstein Capital LLC acquired a new stake in shares of Stryker during the 2nd quarter valued at about $43,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK opened at $358.24 on Tuesday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The business’s 50 day moving average is $377.43 and its two-hundred day moving average is $381.12. The company has a market cap of $136.96 billion, a P/E ratio of 47.45, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a dividend of $0.84 per share. The ex-dividend date was Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.15%.

Analyst Ratings Changes

Several research firms recently weighed in on SYK. Rothschild & Co Redburn began coverage on Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Needham & Company LLC boosted their target price on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Redburn Partners set a $420.00 target price on Stryker in a report on Thursday, September 18th. Finally, Truist Financial restated a “hold” rating and issued a $392.00 target price (down from $407.00) on shares of Stryker in a report on Monday. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $433.37.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.